Clinical Research Directory
Browse clinical research sites, groups, and studies.
Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer
Sponsor: University Health Network, Toronto
Summary
This is a single-arm phase II prospective trials that is recruiting 100 participants. The study population that is being investigated are patients with localized high-risk or node-positive prostate cancer. Participants will receive external beam radiotherapy as a moderately hypofractionated boost to the prostate with pelvic radiation therapy. Androgen deprivation therapy will be prescribed at the discretion of the treating physician as per standard of care.
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2022-07-18
Completion Date
2030-07
Last Updated
2024-06-18
Healthy Volunteers
No
Conditions
Interventions
Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy)
External beam radiotherapy- 60 Gy in 20 fractions to the prostate, 48 Gy in 20 fractions to the pelvis, 68 Gy in 20 fraction optional boost to prostatic dominant intraprostatic lesion, 55 Gy in 20 fraction optional boost to involved pelvic lymph nodes
Locations (1)
Princess Margaret Cancer Center
Toronto, Ontario, Canada